-
1
-
-
0036307453
-
Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics
-
10.2165/00023210-200216070-00004, 12056922
-
Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002, 16:473-484. 10.2165/00023210-200216070-00004, 12056922.
-
(2002)
CNS Drugs
, vol.16
, pp. 473-484
-
-
Csernansky, J.G.1
Schuchart, E.K.2
-
2
-
-
0842263782
-
A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia
-
10.1016/S0924-977X(03)00109-3, 15013023
-
Bhanji NH, Chouinard G, Margolese H. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004, 14:87-92. 10.1016/S0924-977X(03)00109-3, 15013023.
-
(2004)
Eur Neuropsychopharmacol
, vol.14
, pp. 87-92
-
-
Bhanji, N.H.1
Chouinard, G.2
Margolese, H.3
-
3
-
-
74549129561
-
Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review
-
10.4088/PCC.08r00612, 2736032, 19750066
-
Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 2009, 11:147-154. 10.4088/PCC.08r00612, 2736032, 19750066.
-
(2009)
Prim Care Companion J Clin Psychiatry
, vol.11
, pp. 147-154
-
-
Masand, P.S.1
Roca, M.2
Turner, M.S.3
Kane, J.M.4
-
4
-
-
79958233416
-
A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia
-
10.1176/appi.ajp.2011.10081224, 21362741
-
Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011, 168:603-609. 10.1176/appi.ajp.2011.10081224, 21362741.
-
(2011)
Am J Psychiatry
, vol.168
, pp. 603-609
-
-
Tiihonen, J.1
Haukka, J.2
Taylor, M.3
Haddad, P.M.4
Patel, M.X.5
Korhonen, P.6
-
5
-
-
0036773689
-
Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature
-
10.4088/JCP.v63n1007, 12416599
-
Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909. 10.4088/JCP.v63n1007, 12416599.
-
(2002)
J Clin Psychiatry
, vol.63
, pp. 892-909
-
-
Lacro, J.P.1
Dunn, L.B.2
Dolder, C.R.3
Leckband, S.G.4
Jeste, D.V.5
-
6
-
-
72849116914
-
A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome
-
10.4088/JCP.09m05284yel, 19906343
-
Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009, 70:1397-1406. 10.4088/JCP.09m05284yel, 19906343.
-
(2009)
J Clin Psychiatry
, vol.70
, pp. 1397-1406
-
-
Weiden, P.J.1
Schooler, N.R.2
Weedon, J.C.3
Elmouchtari, A.4
Sunakawa, A.5
Goldfinger, S.M.6
-
7
-
-
4544230571
-
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics
-
10.4088/JCP.v65n0809, 15323593
-
Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004, 65:1084-1089. 10.4088/JCP.v65n0809, 15323593.
-
(2004)
J Clin Psychiatry
, vol.65
, pp. 1084-1089
-
-
Lindenmayer, J.P.1
Eerdekens, E.2
Berry, S.A.3
Eerdekens, M.4
-
8
-
-
76149108173
-
Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety
-
10.1002/hup.1085, 20041474
-
Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. Hum Psychopharmacol 2010, 25:37-46. 10.1002/hup.1085, 20041474.
-
(2010)
Hum Psychopharmacol
, vol.25
, pp. 37-46
-
-
Hawley, C.1
Turner, M.2
Latif, M.A.3
Curtis, V.4
Saleem, P.T.5
Wilton, K.6
-
9
-
-
72849146000
-
Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia
-
10.1002/hup.1057, 19790174
-
Kim SW, Shin IS, Kim JM, Lee SH, Lee YH, Yang SJ, Yoon JS. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Hum Psychopharmacol 2009, 24:565-573. 10.1002/hup.1057, 19790174.
-
(2009)
Hum Psychopharmacol
, vol.24
, pp. 565-573
-
-
Kim, S.W.1
Shin, I.S.2
Kim, J.M.3
Lee, S.H.4
Lee, Y.H.5
Yang, S.J.6
Yoon, J.S.7
-
10
-
-
77950915234
-
Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome
-
10.1002/hup.1108, 20373476
-
Lloyd K, Latif MA, Simpson S, Shrestha KL. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Hum Psychopharmacol 2010, 25:243-252. 10.1002/hup.1108, 20373476.
-
(2010)
Hum Psychopharmacol
, vol.25
, pp. 243-252
-
-
Lloyd, K.1
Latif, M.A.2
Simpson, S.3
Shrestha, K.L.4
-
11
-
-
9644257391
-
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
-
10.1016/j.euroneuro.2004.07.003, 15572280
-
Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David AS. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005, 15:111-117. 10.1016/j.euroneuro.2004.07.003, 15572280.
-
(2005)
Eur Neuropsychopharmacol
, vol.15
, pp. 111-117
-
-
Chue, P.1
Eerdekens, M.2
Augustyns, I.3
Lachaux, B.4
Molcan, P.5
Eriksson, L.6
Pretorius, H.7
David, A.S.8
-
12
-
-
33746874424
-
A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study
-
10.1055/s-2006-946703, 16900609
-
Bai YM, Chen TT, Wu B, Hung CH, Lin WK, Hu TM, Lin CY, Chou P. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 2006, 39:135-141. 10.1055/s-2006-946703, 16900609.
-
(2006)
Pharmacopsychiatry
, vol.39
, pp. 135-141
-
-
Bai, Y.M.1
Chen, T.T.2
Wu, B.3
Hung, C.H.4
Lin, W.K.5
Hu, T.M.6
Lin, C.Y.7
Chou, P.8
-
13
-
-
33846235456
-
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study
-
10.1097/JCP.0b013e31802dda4a, 17224706
-
Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007, 27:6-14. 10.1097/JCP.0b013e31802dda4a, 17224706.
-
(2007)
J Clin Psychopharmacol
, vol.27
, pp. 6-14
-
-
Kramer, M.1
Simpson, G.2
Maciulis, V.3
Kushner, S.4
Vijapurkar, U.5
Lim, P.6
Eerdekens, M.7
-
14
-
-
74449091850
-
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study
-
10.1016/j.schres.2009.10.026, 19959339
-
Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010, 116:107-117. 10.1016/j.schres.2009.10.026, 19959339.
-
(2010)
Schizophr Res
, vol.116
, pp. 107-117
-
-
Hough, D.1
Gopal, S.2
Vijapurkar, U.3
Lim, P.4
Morozova, M.5
Eerdekens, M.6
-
15
-
-
67650495255
-
Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER
-
10.1185/03007990903010623, 19469696
-
Knapp M, Locklear J, Jarbrink K. Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER. Curr Med Res Opin 2009, 25:1593-1603. 10.1185/03007990903010623, 19469696.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 1593-1603
-
-
Knapp, M.1
Locklear, J.2
Jarbrink, K.3
-
16
-
-
69849099693
-
Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic
-
10.2165/11316870-000000000-00000, 19725593
-
Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet 2009, 48:585-600. 10.2165/11316870-000000000-00000, 19725593.
-
(2009)
Clin Pharmacokinet
, vol.48
, pp. 585-600
-
-
Samtani, M.N.1
Vermeulen, A.2
Stuyckens, K.3
|